IceCure Medical gets China patent for cryoablation tech
Ticker: ICCM · Form: 6-K · Filed: Dec 5, 2025 · CIK: 1584371
Sentiment: bullish
Topics: patent, medical-devices, china
TL;DR
IceCure Medical secured a China patent for cryoablation tech, boosting IP.
AI Summary
On December 5, 2025, IceCure Medical Ltd. announced it received a notice of patent allowance in China for a novel cryogen flow control system. This system is designed to optimize patient cryoablation outcomes. The company filed this information as part of a Form 6-K report.
Why It Matters
This patent allowance in China could strengthen IceCure Medical's intellectual property portfolio and potentially expand its market reach for cryoablation solutions.
Risk Assessment
Risk Level: low — The filing is a routine report of a patent allowance, which is generally positive news with low immediate risk.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and recipient of the patent
- China (country) — Jurisdiction where the patent was allowed
- December 5, 2025 (date) — Date of the press release and filing
FAQ
What is the specific title of the press release filed with this 6-K?
The press release is titled "IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes."
What is the Commission File Number for IceCure Medical Ltd.?
The Commission File Number is 001-40753.
In which country did IceCure Medical Ltd. receive a notice of patent allowance?
IceCure Medical Ltd. received a notice of patent allowance in China.
What is the primary function of the newly patented cryogen flow control system?
The system is designed to optimize patient cryoablation outcomes.
What form is being used for this filing?
This filing is on Form 6-K, a Report of Foreign Private Issuer.
Filing Stats: 317 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2025-12-05 08:45:13
Filing Documents
- ea0268574-6k_icecure.htm (6-K) — 12KB
- ea026857401ex99-1_icecure.htm (EX-99.1) — 10KB
- 0001213900-25-118481.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: December 5, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 3